000513.SZ
丽珠集团
SZSE · Healthcare · C 制造业 · CN
CNY 26.34
−9.98%Aug 28, 2026, 02:07 UTC
Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.
Source:Aug 23, 2026, 10:03 UTC
Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.
Source:Aug 21, 2026, 10:28 UTC
Livzon Pharmaceutical Group announced its interim results for the six months ended June 2026, with revenue of RMB 4.99967 billion, down 20.28% year-on-year, and net profit of RMB 932 million, down 27.23% year-on-year.
Source: